LATEST NEWS
May 02, 2025 | Press Releases
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United KingdomMarch 07, 2025 | Press Releases
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and OlderFebruary 25, 2025 | Press Releases
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine December 16, 2024 | Press Releases
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India October 29, 2024 | Press Releases
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine September 19, 2024 | Press Releases
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for AdolescentsSeptember 12, 2024 | Press Releases
Bavarian Nordic Provides Update on the Mpox Vaccine Supply SituationSeptember 05, 2024 | Press Releases
First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of CongoAugust 27, 2024 | Press Releases
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in SingaporeAugust 17, 2024 | Press Releases
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders